Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 8
Submit an article Journal homepage
181
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Clinical trials of active cancer immunotherapy

where are the right end points?

Sergiusz Nawrocki Department of Radiotherapy, ZOZ MSWiA z Warmińsko-Mazurskim Centrum Onkologii, Al. Wojska Polskiego 37, 10-228 Olsztyn, Poland
, MD PhD &
Andrzej Mackiewicz University School of Medical Sciences and Great Poland Cancer Centre, Department of Cancer Immunology, Chair of Medical Biotechnology, Ul. Garbary 15, 61-866 Poznań, Poland [email protected]
, MD PhD
Pages 1137-1141 | Published online: 09 Aug 2007

Bibliography

  • HOOS A, PARMIANI G, HEGE K et al.: A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. (2007) 30:1-15.
  • MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6:409-414.
  • ROSENBERG SA, YANG JC, RESTIFO N: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10:909-915.
  • MACKIEWICZ A, GORNY A, LACIAK M et al.: Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting IL-6 and soluble interleukin 6 receptor. Hum. Gene Ther. (1995) 6:805-811.
  • NAWROCKI S, MURAWA P, MALICKI J et al.: Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol. Lett. (2000) 15:81-86.
  • BOON T, COULIE PG, VAN DEN EYNDE BJ et al.: Human T cell responses against melanoma. Ann. Rev. Immunol. (2006) 24:175-208.
  • THERASSE P, ARBUCK SG, EISENHAUER EA et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. (2000) 92:205-216.
  • VON HOFF DD: There are no bad anticancer agents, only bad clinical trial designs – twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. (1998) 4:1079-1089.
  • NAGORSEN D, THIEL E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. (2006) 12:3064-3069.
  • SEYMOUR L: The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr. Pharm. Des. (2002) 8:2279-2284.
  • SCHILSKY RL: End points in cancer clinical trials and drug approval process. Clin. Cancer Res. (2002) 8:935-938.
  • SIMON RM, STEINBERG SM, HAMILTON M et al.: Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. (2001) 19:1848-1854.
  • SIMON RM: Clinical trial designs for therapeutic cancer vaccines. Cancer Treat. Res. (2005) 123:339-350.
  • RUBINSTEIN LV, KORN EL, FREIDLIN B et al.: Design issues of randomized Phase II trials and a proposal for Phase II screening trials. J. Clin. Oncol. (2005) 23:7199-7206.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.